Departamento de Biomedicina - Unidade de Farmacologia e Terapêutica, Faculdade de Medicina, Universidade do Porto, Rua Dr. Plácido da Costa, S/N, Edifício Poente, Piso 3, 4200-450 Porto, Portugal; Centro de Investigação Farmacológica e Inovação Medicamentosa, Universidade do Porto (MedInUP), Alameda Professor Hernâni Monteiro, 4200-319, Porto, Portugal; Centro Hospitalar Universitário de São João, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.
Departamento de Biomedicina - Unidade de Farmacologia e Terapêutica, Faculdade de Medicina, Universidade do Porto, Rua Dr. Plácido da Costa, S/N, Edifício Poente, Piso 3, 4200-450 Porto, Portugal; Centro de Investigação Farmacológica e Inovação Medicamentosa, Universidade do Porto (MedInUP), Alameda Professor Hernâni Monteiro, 4200-319, Porto, Portugal.
Biomed Pharmacother. 2021 Jan;133:110938. doi: 10.1016/j.biopha.2020.110938. Epub 2020 Nov 7.
We investigated oxidative stress and RAAS biomarkers, as well as their association, in chronic heart failure (CHF) patients on optimized medical therapy, stratified by disease severity or by renal function. Since vitamin D has been shown to attenuate RAAS activation and oxidative stress, we further evaluated the relationship between vitamin D, RAAS and oxidative stress in CHF patients with or without renal impairment. Sixty CHF outpatients were included and stratified by disease severity or by renal function. We quantified urinary hydrogen peroxide, plasma and urinary isoprostanes, plasma total antioxidant status, urinary angiotensinogen (intrarenal RAAS activation biomarker) and plasma angiotensinogen, plasma renin and aldosterone concentration, serum angiotensin-converting enzyme (ACE) activity, plasma angiotensin peptides, and serum total 25-hydroxyvitamin D (S-total 25(OH)D). Severe CHF patients had higher urinary isoprostanes (p = 0.002) and lower S-total 25(OH)D (p = 0.006) compared to mild-to-moderate patients, but no differences were observed for other redox or RAAS biomarkers. Patients with impaired renal function (iRF) had higher urinary angiotensinogen (p = 0.003) and lower S-total 25(OH)D (p = 0.028) compared to those with normal renal function (nRF), while no differences were observed for the remaining RAAS and redox parameters. Several positive correlations between oxidative stress and RAAS biomarkers were detected in iRF patients, while in patients with nRF these correlations were primarily inverse. In CHF-iRF patients, S-25(OD)D was inversely associated with urinary isoprostanes, which in turn were positively associated with plasma angiotensinogen and serum ACE. In conclusion, CHF patients with renal function impairment have increased intrarenal RAAS activation and lower vitamin D values and might benefit from the combination of RAAS blockers with vitamin D and/or antioxidants.
我们研究了在优化药物治疗的基础上,根据疾病严重程度或肾功能对慢性心力衰竭(CHF)患者的氧化应激和 RAAS 生物标志物及其相关性,由于维生素 D 已被证明可减弱 RAAS 激活和氧化应激,我们进一步评估了有或没有肾功能损害的 CHF 患者中维生素 D、RAAS 和氧化应激之间的关系。共纳入 60 例 CHF 门诊患者,并根据疾病严重程度或肾功能进行分层。我们定量测定了尿液过氧化氢、血浆和尿液异前列烷、血浆总抗氧化状态、尿液血管紧张素原(肾内 RAAS 激活生物标志物)和血浆血管紧张素原、血浆肾素和醛固酮浓度、血清血管紧张素转换酶(ACE)活性、血浆血管紧张素肽和血清总 25-羟维生素 D(S-总 25(OH)D)。与轻度至中度患者相比,严重 CHF 患者的尿液异前列烷(p=0.002)更高,S-总 25(OH)D(p=0.006)更低,但其他氧化还原或 RAAS 生物标志物无差异。肾功能不全(iRF)患者的尿液血管紧张素原(p=0.003)更高,S-总 25(OH)D(p=0.028)更低,而正常肾功能(nRF)患者无差异,而其他 RAAS 和氧化还原参数则无差异。在 iRF 患者中,氧化应激和 RAAS 生物标志物之间检测到一些正相关,而在 nRF 患者中,这些相关性主要是负相关。在 CHF-iRF 患者中,S-25(OD)D 与尿液异前列烷呈负相关,而尿液异前列烷又与血浆血管紧张素原和血清 ACE 呈正相关。总之,肾功能不全的 CHF 患者肾内 RAAS 激活增加,维生素 D 值降低,可能受益于 RAAS 阻滞剂与维生素 D 和/或抗氧化剂的联合治疗。